SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Sunovion Pharmaceuticals Inc. Announces FDA Acceptance of 2 sNDAs for Latuda® as Monotherapy and Adjunctive Therapy in Adult Patients With Depressive Episodes Associated with Bipolar I Disorder